<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00632099</url>
  </required_header>
  <id_info>
    <org_study_id>#5568</org_study_id>
    <secondary_id>R01DA022218</secondary_id>
    <secondary_id>DPMCDA</secondary_id>
    <nct_id>NCT00632099</nct_id>
  </id_info>
  <brief_title>Progesterone Treatment for Cocaine-dependent Women: A Pilot Study</brief_title>
  <acronym>PROG</acronym>
  <official_title>Progesterone Treatment for Cocaine-dependent Women: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot treatment trial is to evaluate the efficacy of oral micronized PROG
      in cocaine-dependent women. Since we have shown (Evans &amp; Foltin, 2006) that oral micronized
      PROG attenuates the positive subjective effects of smoked cocaine in females, but not in
      males, and we have preliminary data indicating that oral micronized PROG also reduces smoked
      cocaine self-administration in the laboratory, PROG appears to be an ideal potential
      candidate medication to evaluate in cocaine-dependent women. Prior to randomization to
      treatment, women will reside inpatient for one week to ensure cocaine abstinence since one of
      the primary outcome measures will be time to cocaine relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aims: The primary aims will be directed at treatment efficacy. Relatively unique to
      cocaine treatment trials, one of the principal outcome measures will be time to cocaine
      relapse. We hypothesize that maintenance on PROG will increase the time to cocaine relapse
      compared to maintenance on placebo (PBO). Another cocaine-related efficacy endpoint will be
      the proportion of patients who achieve at least 2 consecutive weeks of cocaine abstinence
      (based on urine toxicology results) during the double-blind treatment phase. Lastly, the
      proportion of cocaine-negative urines collected throughout the treatment trial will be
      measured. We hypothesize that women in the PROG group will show a greater reduction in
      cocaine use compared to those in the PBO group.

      Secondary Aims: 1) Determine if response to laboratory stressors will predict treatment
      outcome. We hypothesize that those women with the greatest stress response will do worse in
      treatment and that maintenance on PROG will reduce stress/anxiety and thereby improve
      treatment outcome. 2) Determine if treatment retention is better in the PROG group compared
      to the PBO group and determine if maintenance on PROG improves overall functioning compared
      to maintenance on PBO based on the Clinical Global Inventory (CGI). We hypothesize that women
      in the PROG group will have better treatment retention and improvement in CGI scores compared
      to women in the PBO group.

      Tertiary Aims: To conduct exploratory analyses to determine whether 1) trauma history is
      related to treatment outcomes and 2) improvements in treatment outcome measures are related
      to decreases in HIV high-risk behaviors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Abstinence Based on Urine Toxicology Results</measure>
    <time_frame>during last 3 weeks of the trial</time_frame>
    <description>Percentage of patients cocaine abstinent during last 3 weeks of the study (weeks 7-9)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral micronized progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral micronized progesterone (up to 400 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral micronized progesterone</intervention_name>
    <description>Oral micronized progesterone (up to 400 mg/day), suspended in olive oil</description>
    <arm_group_label>Oral micronized progesterone</arm_group_label>
    <other_name>Progesterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Women between the ages of 18-60 who meet criteria for current cocaine dependence
             (DSM-IV-TR). Volunteers may meet criteria for abuse or dependence on nicotine,
             marijuana or alcohol, as long as the dependence is secondary to cocaine dependence and
             does not require any medical intervention (see additional exclusions for alcohol
             dependence below).

             2. Use cocaine by the smoked or intranasal route at least four days in the past month,
             with at least weekly cocaine use.

             3. Women with regular menstrual cycles (24-45 days) who are not pregnant, based on the
             results of a blood pregnancy test drawn at the time of screening. They must agree to
             use a barrier method of contraception with proven efficacy and agree not to become
             pregnant during the study. To confirm this, urine pregnancy tests will be conducted
             weekly.

             4. Women must be capable of giving informed consent and capable of complying with
             study procedures.

        Exclusion Criteria:

          -  1. Meets DSM-IV-TR criteria for bipolar disorder, Schizophrenia, or any psychotic
             disorder other than transient psychosis due to drug abuse.

             2. Individuals with any current Axis I psychiatric disorder as defined by DSM-IV-TR
             supported by the SCID-I/P that in the investigator's judgment are unstable or would be
             disrupted by study medication. Disorders that are stable on psychotherapy or
             pharmacotherapy will not be exclusionary. Individuals will be permitted to take
             prescribed zolpidem and zaleplon or other medications for insomnia if there is no
             evidence of dependence on these substances.

             3. Individuals with current major depressive disorder.

             4. Individuals physiologically dependent on any other drugs (excluding nicotine or
             cannabis) that require medical intervention will be excluded and referred for
             treatment. Individuals with severe alcohol dependence , even without physiological
             dependence, or with any known alcohol-related diseases will also be excluded.

             5. Females who have any of the following medical contraindications: undiagnosed
             abnormal genital bleeding, known or suspected history of breast or genital cancer,
             active deep vein thrombosis, pulmonary embolism, or history of these conditions,
             active or recent (within last year) arterial thromboembolic diseases (e.g., stroke,
             myocardial infarction), liver dysfunction.

             6. Females who are cognitively impaired or have a chronic organic mental disorder.

             7. Individuals with current suicidal risk.

             8. Individuals with coronary vascular disease as indicated by history or suspected by
             abnormal ECG or history of cardiac symptoms.

             9. Unstable physical disorders which might make participation hazardous such as
             uncontrolled hypertension (Blood pressure &gt; 150/ 90, or Heart Rate &gt; 100 when sitting
             quietly), acute hepatitis (patients with chronic mildly elevated transaminases &lt; 3x
             upper limit of normal are acceptable), or uncontrolled diabetes.

             10. Individuals with a history of seizures.

             11. Women who are pregnant or nursing.

             12. Individuals who are legally mandated (e.g., to avoid incarceration, monetary or
             other penalties, etc.) to participate in substance abuse treatment program.

             13. Females with a known or suspected hypersensitivity to oral micronized
             progesterone.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzette Evans, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stars.columbia.edu/</url>
    <description>Substance Treatment and Research Service of Columbia University</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2008</study_first_posted>
  <results_first_submitted>April 9, 2014</results_first_submitted>
  <results_first_submitted_qc>April 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2014</results_first_posted>
  <last_update_submitted>April 9, 2014</last_update_submitted>
  <last_update_submitted_qc>April 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>treatment</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Matched Placebo</title>
          <description>matched placebo
Placebo: matched placebo</description>
        </group>
        <group group_id="P2">
          <title>Oral Micronized Progesterone</title>
          <description>Oral micronized progesterone (up to 400 mg/day)
Oral micronized progesterone: Oral micronized progesterone (up to 400 mg/day), suspended in olive oil</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Matched Placebo</title>
          <description>matched placebo
Placebo: matched placebo</description>
        </group>
        <group group_id="B2">
          <title>Oral Micronized Progesterone</title>
          <description>Oral micronized progesterone (up to 400 mg/day)
Oral micronized progesterone: Oral micronized progesterone (up to 400 mg/day), suspended in olive oil</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="9"/>
                    <measurement group_id="B2" value="45" spread="8"/>
                    <measurement group_id="B3" value="43" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Abstinence Based on Urine Toxicology Results</title>
        <description>Percentage of patients cocaine abstinent during last 3 weeks of the study (weeks 7-9)</description>
        <time_frame>during last 3 weeks of the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Matched Placebo</title>
            <description>matched placebo
Placebo: matched placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Micronized Progesterone</title>
            <description>Oral micronized progesterone (up to 400 mg/day)
Oral micronized progesterone: Oral micronized progesterone (up to 400 mg/day), suspended in olive oil</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Abstinence Based on Urine Toxicology Results</title>
          <description>Percentage of patients cocaine abstinent during last 3 weeks of the study (weeks 7-9)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks of study participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Matched Placebo</title>
          <description>matched placebo
Placebo: matched placebo</description>
        </group>
        <group group_id="E2">
          <title>Oral Micronized Progesterone</title>
          <description>Oral micronized progesterone (up to 400 mg/day)
Oral micronized progesterone: Oral micronized progesterone (up to 400 mg/day), suspended in olive oil</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <description>Patient experienced pain and floater and was diagnosed with uveitis.
The patient was followed by her ophthalmologist and two weeks later and had outpatient laser surgery for retinal detachment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>increased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>swollen hands</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>increased libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>hot flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain/cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>breast tenderness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Given the limited sample size, it was not possible to adequately determine whether OM-PROG may be an effective treatment for cocaine-dependence in women, but it was well tolerated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Suzette Evans</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-6136</phone>
      <email>se18@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

